Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12)

源自亚美尼亚仓鼠宿主的抗小鼠 TNF alpha IgG 抗体抑制剂 Anti-Mouse TNF alpha Antibody (TN3-19.12) 可中和从 LNC-8 细胞获得的上清液中的细胞毒性,减轻 LNC-8 细胞异种移植小鼠模型中实验性自身免疫性脑脊髓炎 (EAE) 的症状和严重程度,预防非肥胖糖尿病 (NOD) 小鼠发生糖尿病,并在 CD2F1 小鼠中显示出明显的放射增敏作用。
Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12)
产品编号: MS-V40318 纯度: 99.24% 分子量: 150 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
(100μg)
询价
询价
(100µg)
询价
询价

产品描述

源自亚美尼亚仓鼠宿主的抗小鼠 TNF alpha IgG 抗体抑制剂 Anti-Mouse TNF alpha Antibody (TN3-19.12) 可中和从 LNC-8 细胞获得的上清液中的细胞毒性,减轻 LNC-8 细胞异种移植小鼠模型中实验性自身免疫性脑脊髓炎 (EAE) 的症状和严重程度,预防非肥胖糖尿病 (NOD) 小鼠发生糖尿病,并在 CD2F1 小鼠中显示出明显的放射增敏作用。

生物实验数据

生物活性 Anti-Mouse TNF alpha Antibody (TN3-19.12), an IgG antibody inhibitor against mouse TNF alpha derived from an Armenian hamster host, neutralizes the cytotoxicity obtained from LNC-8 cell supernatants, alleviates the symptoms and severity of experimental autoimmune encephalomyelitis (EAE) in LNC-8 cell xenograft mouse models, prevents the onset of diabetes in non-obese diabetic (NOD) mice, and exhibits significant radiosensitizing effects in CD2F1 mice.
IC50 & Target

TNF alpha

体外研究
(In Vitro)

Anti-Mouse TNF alpha Antibody (TN3-19.12) (850 ng, 1 h) 可中和上清液中从 LNC-8 细胞获得的细胞毒性。

体内研究
(In Vivo)

Anti-Mouse TNF alpha Antibody (TN3-19.12) (0.3-1 mg,腹腔注射,单剂量) 可减轻 LNC-8 细胞异种移植小鼠模型中实验性自身免疫性脑脊髓炎 (EAE) 的症状和严重程度。

Anti-Mouse TNF alpha Antibody (TN3-19.12) (20 μg/g or 100 μg/injection,腹腔注射,隔天 1 次,持续 21-24 天) 可预防非肥胖糖尿病小鼠 (0-4 周龄) 发生糖尿病。

Anti-Mouse TNF alpha Antibody (TN3-19.12) (50-100 μg,腹腔注射,单剂量) 可降低受辐照的 CD2F1 小鼠的存活率。

Anti-Mouse TNF alpha Antibody (TN3-19.12) (200 μg,腹腔注射,给 LPS (MS-X54539) 前 20 h) 可降低 CD2F1 小鼠中脂多糖诱导的辐射防护作用。

Animal Model: Mice injected with LNC-8 cells intraperitoneally
Dosage: 0.3 mg
Administration: Intraperitoneal injection
Result: Resulted in a dramatic reduction in the symptoms and severity of EAE (experimental allergic encephalomyelitis).
Alleviated meningeal infiltration.
Animal Model: Mice injected with LNC-8 cells intravenously
Dosage: 1 mg
Administration: Intraperitoneal injection
Result: Reduced the symptoms and severity of EAE.
Reduced the incidence of disease from 89% in the PBS to 20%.
Animal Model: Newborn female NOD mice
Dosage: 20 μg/g
Administration: Intraperitoneally every other day for 24 days
Result: None of mice developed diabetes even after 30 week of age.
Had no significant effect on mouse development and growth, or mortality.
Had no dramatic influence on the development of lymphoid tissues.
Did not potentiate the ability to respond to GAD67, GAD65, CPH, peripherin, and HSP60 at 10 week of age.
Enhanced responses to HEL and OVA.
Inhibited insulitis (only 27% of mice developed a low or moderate degree of insulitis compared to PBS-treated of 100%).
Animal Model: 2-week-old female NOD mice
Dosage: 20 μg/g
Administration: Intraperitoneally every other day for 3 weeks
Result: None of mice developed diabetes even after 34 week of age.
Animal Model: 4-week-old female NOD mice
Dosage: 100 μg/injection
Administration: Intraperitoneally every other day for 3 weeks
Result: Partly prevented disease (about 50%).
Animal Model: Irradiated CD2F1 mice (male, 8-10 week)
Dosage: 100 μg 20 h before irradiation or at 50 μg 1 h after irradiation
Administration: Intraperitoneal injection
Result: Reduced survival of irradiated CD2F1 mice.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 150 kDa

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础